[Circadian urinary excretion of catecholamine, plasma atrial natriuretic peptide, endothelin and neuropeptide Y in obese patients with hypertension].
Obesity increases the risk of developing hypertension by two-to fourfold, with more that one third of all cases of hypertension attributable to obesity. The present study tested the role of atrial natriuretic peptide (ANP), endothelin-1,2 (ET-1,2) and neuropeptide Y (NPY) in pathogenesis of obesity hypertension. The plasma concentrations of ANP, ET-1,2 and NPY were determined in the peripheral venous blood by radioimmunoassay in 27 obese hypertensive patients (group I), in 24 obese normotensive patients (group II), and in 35 normal subjects (group III).


RESULTS
Mean plasma ANP was significantly higher in obese than in normal subjects. ANP levels were higher in patients group I than in those group II and I. In patients of group I plasma ANP concentrations correlated with III BMI and mean blood pressure. Plasma levels of ET-1,2 and NPY were similar in patients group I, II and III.
Halawa
B
B
Katedra i Klinika Kardiologii AM we Wrocławiu.
Mazurek
W
W
D000293:Adolescent; D000328:Adult; D000368:Aged; D009320:Atrial Natriuretic Factor / Q000097:blood; D002395:Catecholamines / Q000652:urine*; D019332:Endothelin-1 / Q000097:blood; D019333:Endothelin-2 / Q000097:blood; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D009478:Neuropeptide Y / Q000097:blood; D009765:Obesity / Q000150:complications / Q000378:metabolism*; D010455:Peptides / Q000097:blood*
D002395:Catecholamines; D019332:Endothelin-1; D019333:Endothelin-2; D009478:Neuropeptide Y; D010455:Peptides; D009320:Atrial Natriuretic Factor
Dobowe wydalanie katecholamin z moczem oraz stezenia w surowicy przedsionkowego peptydu natriuretycznego, endoteliny i neuropeptydu y u osób otyłych chorych na nadciśnienie tetnicze.